Comunicación Nº: 025

Características morfológicas y biológicas del carcinoma de mama en mujeres jóvenes.

Dres. M de la Vega*, P Menéndez**, MP Alvarez, C González-Rey.

*Hptal. Ntra. Sra. del Pino, Las Palmas GC; **Hptal. Monte Naranco, Oviedo; Hptal. General de Asturias, Oviedo.

Dirección: Hospital Nuestra Señora del Pino. C/ Ángel Guimera, 97
35004 Las Palmas de Gran Canaria. España

[Título] [Introducción] [Material y Métodos] [Resultados] [Discusión]


1.Waalen J. Breast cancer in young women: questions outpace answers.J Nat Cancer Inst 1992;84:1143-1145.

2.Lee CG, McCormic B, Mazumdar M, Vetto J, Borgen PI. Infiltrating breast carcinoma in patients age 30 years and younger: long term outcome for life, relapse, and second primary tumors. Int J Radiation Oncology Biol Phys 1992;23:969-975.

3.Stoll BA. High risk breast cancer in young women. Eur J Cancer 1991;27:808.

4.Hermanek P, Sobin LH. UICC TNM Classificatio of Malignant Tumors (4 de). Springer-Verlag Berlin 1987:94-99.

5..Friedell GH, Soto EA, Kumaoka S, Abe O, Hayward JL, Bulbrook RD. Sinus hystiocytosis in british and japanese patients with breast cancer. Lancet 1974;2:1228-1229.

6.World Health Organization. Histological typing of breast tumors. Geneve, Switzerland 1981.

7.Bloom BG, Richardson WW.Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-377.

8.Black MM, Speer FD. Nuclear structure in cancer tissues. Surg Gynecol Obstet 1957;105:97-102.

9.Gilchrist KW, Gray R, Fowble B, Tormey DC, Taylor SG. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer.A 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Oncol 1993;11:1929-1935.

10.Fisher ER, Kotwal N, Hermann C, Fisher B. Types of tumor lymphoid response and sinus histiocytosis. Arch Pathol Lab Med 1983;107:222-227.

11.Martínez-Hernández A, Francis DJ, Silverberg SG. Elastosis and other stromal reactions in benign and malignant breast tissue. Cancer 1977;40:700-706.

12.Silberberg SG, Chitale AR, Levitt SH. Prognostic significance of tumor margins in mammary carcinoma. Arch Surg 1971;102:450-454.

13.Pinder SE, Ellis IO, Galea M, O´Rouke S, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer III. Vascular invasion: relationship with recurrence and survival in large study with long-term follow-up. Histopathology 1994,24:41-47.

14.Anastassiades O, Iakovou E, Stavridou N, Gogas J, Karameris A. Multicentricity in breast cancer. A study of 366 cases. Am J Clin Pathol 1993;99:238-243.

15.Van de Velde CJH, Gallager HS, Gianco GG. Prognosis in node negative breast cancer. Breast Cancer Res Treat 1986;8:189-196.

16.Azzopardi JG. Mammography En: Problems in breast pathology. Bennington JJ (de). WB Saunders Company Londres 1989.

17.-Foekens JA, Rio MC, Seguin P, van Putten WLJ, Fauque J, Nap M, Klijn JGM, Chambon P. Prediction of relapse and survival in breast cancer patients by pS2 protein status.Cancer Res 1990;50:3832-3837.

18.Hedley DW, Clark GM, Cornelisse CJ y cols. Consensus reiew of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 1993;14:482-485.

19.-Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 1996;77:97-103

20.-Alexieva-Figusch J, Van Putten WLJ, Blankestein MA, Blonk-Van Der Wijst J, Klijn JGM. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer. Cancer 1988;61:758-768.

21.-Wellings SR, Alpers CE. Apocrine cystic metaplasic: subgross pathology and prevalence in cancer-associated versus random autopsy breast. Hum Pathol 1987;18.381-386.

22.-Silfversward C, Gustafsson SA, Humla S, Nordenskjold B, Wallgren A, Wrange O. Estrogen receptor concentrations in 269 cases of histologically classified human breast cancer. Cancer 1980;45:001-2005.

23.-Fisher ER, Redmond CK, Liu H, Rockette H, Fisher B and collaborating NSABP investigators. Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer 1980;45:349-353.

24.-Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient Characteristics in human breast cancer. J Clin Oncol 1984;2:1102-1109.

25.-Clark GM. Do we really need prognostic factors for breast cancer?. Breast Cancer Res Treat 1994;30:117-126.

26.-Henry JA, Bennett MK, Piggott NH, Levett DL, May FEB, Westley BR. Expression of the pNR-2/pS2 protein in diverse human epithelial tumors. Br J Cancer 1991;64;677-682.

27.-Granata G, Coradini D, Cappelleti V, Di Fronzo G. Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. Eur J Cancer 1991,27:970-972.

28.-Mira y López R, Osborne MP, Denalo AJ, Ossowski L. Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: correlation with clinical outcome of anti-estrogen therapy. Int J Cancer 1991;47:827-832.

29.-Yamashita J, Ogawa M, Ineda K, Yamashita S, Nakashime Y, Saishoji T, Nomura K. Breat cancer prognosis is poor whe total plasminogen activator activity is low. Br J Cancer 1993;67.374-378.

30.-Sainsbury JRC, Malcolm AJ, Appleton DR, Farndon JR, Harris AL. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol 1985;38:225-1228.

31.-Quénel N, Wafflart J, Bonichon F,de Mascarel AI, Trojani M, Durand M, Avril A, Coindre JM. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 94 cases. Breast Cancer Res Treat 1995,35:283-291.

32.-Gullick WI. The role of the epidermal growth factor receptor and the c-erbB2 protein in breast cancer. Int J Cancer 1990;suppl 5:55-61.

33.-Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC,McGuire W. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992;23:974-979.

34.-Sharma S,Mishra MC, Kapur BML, Verma K, Nath Y. The prognostic significance of ploiy analysis in operable breast cancer. Cancer 1991;68:2612-2616.

35.-Uterlinde AM, Schipper NW, Bak JPA, Predrese H, Matze E. Limited prognostic value of cellular DNA content to classical and morphometrical parameters in invasive ductal breast cancer. Am J Clin Pathol 1988,89:301-307.

36.-Sharma S, Mishra MC, Kapur BML, Verma K, Nath I. The prognostic significance of ploidy analysis y operable breast cancer. Cancer 1991;68:2612-2616.

37.-Hedley DW, Clark GM, Cornelisse CJ y cols. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 1993;14:482-485.

38.-Klintenberg C,Stal O, Nordenskjold B y cols. Proliferative index, cytosol estrogen receptor and axillary node status are prognostic predictors in human mammary carcinoma. Breast Cancer Res Treat 1986;7:S99-S106.

39.-Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch HT. Hereditary breast cancer. Pathobiology, prognosis and BRCA 1 and BRCA 2 gene linkage. Cancer 1996;77:697-709.